News & Events

October 12, 2021

BrainsWay Announces Prominent Addition to Scientific Advisory Board

Zafiris Daskalakis, MD, PhD to Bring Extensive Research and Clinical Expertise to Assist in Guiding Growth...

September 30, 2021

BrainsWay Announces Data Published in World Psychiatry on Deep Transcranial Magnetic Stimulation (Deep TMS™) for Smoking Addiction

Evidence Supports Use of Deep TMS as a Safe and Effective Treatment for Smoking Addiction BURLINGTON,...

September 20, 2021

MUSC Health among first to offer brain stimulation to try to help smokers quit

Patient testimonials, smoker statistics, and discussion around BrainsWay’s Deep TMS smoking addiction...

September 20, 2021

Mental Health Recap: 4 Must-Read Studies From August 2021

Highlighting the recent FDA clearance for anxious depression with references to the study and a quote...

September 29 - October 2, 2021

Colorado Behavioral Health Council (CBHC)

BrainsWay is attending the 2021 Annual Behavioral Health Training Conference from September 20 through...

October 25 - October 26, 2021

Behavioral Health and Well-Being Summit

BrainsWay is attending the 2021 Behavioral Health and Well-Being Summit from October 25 through to October...

September 9, 2021

BrainsWay featured on CBS News

Dr. Tendler discusses how emerging technologies, such as BrainsWay’s Deep TMS™, offer hope to...

September 7, 2021

Setting Your Company Up for Success When Navigating Coverage Conversations

BrainsWay CEO and President, Christopher von Jako, PhD discusses the navigation, education, and partner...

September 9, 2021

BrainsWay to Participate in Two Upcoming Investor Conferences

BURLINGTON, Mass. and JERUSALEM, Sept. 09, 2021 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

August 30, 2021

BrainsWay to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

BURLINGTON, Mass. and JERUSALEM, August 30, 2021 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

August 25, 2021

Transcranial Magnetic Stimulation Device Cleared for Anxious Depression

Summary of the release and research lending to the FDA-clearance of anxious depression, with quotes from...

August 20, 2021

BrainsWay receives FDA clearance for noninvasive comorbid anxiety, depression treatment

Summary of the release, highlighting how this FDA clearance will allow BrainsWay to increase patient...

August 19, 2021

FDA clearance for Deep TMS system in decreasing anxiety symptoms

FDA Clearance for Deep TMS system in decreasing anxiety symptoms in depressed patients, as well as highlights...

August 19, 2021

FDA Clears Deep TMS System for Comorbid Anxiety Symptoms

Highlighting the FDA clearance announcement as a promising step in managing comorbid anxiety symptoms,...

August 18, 2021

FDA OKs Stimulation Device for Anxiety in Depression

Coverage of BrainsWay receiving FDA Clearance for the treatment of comorbid anxiety symptoms in adults...

August 18, 2021

BrainsWay clinches FDA nod for magnetic stimulation device to ease anxious depression

In-depth explanation as to how Deep TMS’s newest anxiety-depression clearance will help achieve BrainsWay’s...

August 16, 2021

Living with O.C.D. in a Pandemic

Highlights include treatment methods for OCD, emphasizing noninvasive techniques such as TMS as a valuable...

August 18, 2021

FDA Clears BrainsWay Deep TMS™ System for Decreasing Anxiety Symptoms in Depressed Patients

Expanded Depression Indication Further Demonstrates Company’s Leadership Position BURLINGTON, Mass....